234 related articles for article (PubMed ID: 35535633)
1. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.
Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S
Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633
[TBL] [Abstract][Full Text] [Related]
2. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
[TBL] [Abstract][Full Text] [Related]
3. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B; Glickman JW; Golant AK; Dubin C; Marushchak O; Gontzes A; Mikhaylov D; Singer GK; Baum D; Wei N; Sanin A; Gruenstein D; Lebwohl MG; Pavel AB; Guttman-Yassky E
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):134-142. PubMed ID: 34737108
[TBL] [Abstract][Full Text] [Related]
5. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
8. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study.
Cristaudo A; Pigliacelli F; Sperati F; Orsini D; Cameli N; Morrone A; Mariano M
Skin Res Technol; 2021 Sep; 27(5):810-813. PubMed ID: 33651467
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
10. Facial atopic dermatitis may be exacerbated by masks: insights from a multicenter, teledermatology, prospective study during COVID-19 pandemic.
Damiani G; Finelli R; Kridin K; Pacifico A; Bragazzi NL; Malagoli P; Fabbrocini G; Marasca C; Annunziata M; Grada A; Santus P; Savoia P; Gironi LC; Buja A; Linder D; Pigatto PD;
Ital J Dermatol Venerol; 2022 Dec; 157(6):505-509. PubMed ID: 36177781
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice.
Matsutani M; Imai Y; Inoue Y; Nakatani-Kusakabe M; Natsuaki M; Yamanishi K; Kanazawa N
J Dermatol; 2021 Oct; 48(10):1564-1568. PubMed ID: 34155694
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
[TBL] [Abstract][Full Text] [Related]
15. Improve the dupilumab therapy evaluation with dermoscopy and high-frequency ultrasound in moderate-to-severe atopic dermatitis.
Liu Z; Niu Z; Zhang D; Liu J; Zhu Q
Skin Res Technol; 2023 Jan; 29(1):e13260. PubMed ID: 36704877
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study.
Zhou X; Yang G; Chen X; Zhang L
Drugs Aging; 2023 Oct; 40(10):933-940. PubMed ID: 37610613
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
19. Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
Rovati C; Rossi M; Gelmetti A; Tomasi C; Calzavara-Pinton I; Venturini M; Calzavara-Pinton P; Arisi M
Eur J Dermatol; 2021 Dec; 31(6):736-740. PubMed ID: 34704942
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
